v" The rates of survival, tumor recurrence, and tumor progression were analyzed in 225 patients with meningioma who underwent surgery as the only treatment modality between 1962 and 1980. Patients were considered to have a recurrence if their studies verified a mass effect in spite of a complete surgical removal, whereas they were defined as having progression if, after a subtotal excision, there was clear radiological documentation of an increase in the size of their tumor. There were 168 females and 57 males (a ratio of 2.9:1), with a peak incidence of tumor occurrence in the fifth (23%), sixth (29%), and seventh (23%) decades of life. Anatomical locations were the convexity (21%), parasagittal area (17%), sphenoid ridge (16%), posterior fossa (14%), parasellar region (12%), olfactory groove (10%), spine (8%), and orbit (2%). The absolute 5-, 10-, and 15-year survival rates were 83%, 77%, and 69%, respectively.
M
ENINGIOMAS are common tumors and account for 19% of intracranial and 25% of intraspinal neoplasms.~ 1.23 They are generally benign, well circumscribed, and slow growing. However, they can be accompanied by extensive hyperostosis or encasement of major blood vessels, or they may grow to massive proportions, compromising the likelihood of a total surgical removal.
The first successful operation for excision of a meningioma was performed by Pecchioli in Siena in 1835. ~~ Since the classic monograph by Cushing and Eisenhardt, 4 many large series have established the role of surgery in the treatment of meningiomas, and the operative and long-term mortality rates have declined to a low level over the past decades. ~6' 18' 2~ However, many meningiomas recur, especially after incomplete resection. In order to determine the proportion of patients who develop a recurrence and to establish which subgroups of patients may be at higher risk for a recurrence, we have reviewed all cases of meningioma seen at the Massachusetts General Hospital (MGH) from 1962 to 1980. From this study, we have been able to define groups of patients at high risk of recurrence who may be considered for radiation therapy or other adjunctive therapies.
Clinical Material and Methods
The medical records of 373 consecutive patients with the diagnosis of meningioma who were treated at MGH between 1962 and 1980 were reviewed and assessed for tumor recurrence or progression following surgery as the only treatment modality (Table 1) . Some of the patients in this series have been included in other reports on the surgical management of meningiomas. 2~ One hundred and thirty-two patients were excluded from analysis for the following reasons: 47 patients did not undergo surgery, and the diagnosis of meningioma was made at autopsy or during admission for another condition; 18 underwent surgery prior to 1962 and were referred to MGH for recurrence after 1962; 13 were first operated on in another hospital and were referred to MGH for a second operation; eight had multiple meningiomas; six received radiotherapy following primary surgery; five had malignant meningiomas; three had associated neurofibromatosis; and 32 were lost to follow-up evaluation. There were 16 postoperative deaths. Thus, 225 cases were suitable for analysis. Diagnostic evaluation methods varied according to the year of referral and the location of the tumor. In the early years, skull roentgenography, tomography, pneumoencephalography, and gamma-encephalography were used in conjunction with cerebral arteriography. Since 1973, computerized tomography (CT) of the brain has almost always been performed, and other studies have been progressively abandoned, with the exception of arteriography. Myelography of the posterior fossa and spine was performed when indicated.
All operative reports were reviewed and information was obtained regarding the age and sex of the patient, the location of the tumor, the extent of resection, and the results of histological studies. Postoperative death was defined according to the criterion of Cushing and Eisenhardt; 4 that is, "a postoperative fatality is death in hospital from any cause whatsoever following an operation." The extent of surgery (either total or subtotal removal) was determined from the surgeon's operative report. Pathological reports were reviewed and all cases of malignant meningiomas were excluded.
Each case was assessed for tumor recurrence or pro- 
Results

Clinical Characteristics
The distribution of patients according to age and sex is given in Fig. 1 . Most patients were in the fifth, sixth, and seventh decades of life, with 51 (23%), 61 (29%), and 52 (23 %) patients in each group, respectively. There was only one patient younger than 10 years old, and six patients, all women, were more than 80 years old. One hundred and sixty-eight patients were females and 57 were males, for a female to male ratio of 2.94:1.
Tumor Location and Extent of Resection
The most frequent site of meningiomas was the convexity (21% of our series). The parasagittal area and falx were the next most frequently involved sites (17%), followed by the sphenoid ridge (16%), posterior fossa ( 14 %), parasellar region (12 %), olfactory groove ( 10 %), and spine (8%). Orbital meningiomas were rare, with only five cases (2%) in this series (Table 2) .
Of the 225 meningiomas, 145 (64%) were removed completely and 80 (36%) were subtotally resected. Certain tumor sites were associated with a high rate of total removal: these included the convexity (96%), orbit (80%), spine (78%), olfactory groove (77%), and the parasagittal area (76%). For other sites the total resection rate was much lower: 28% for sphenoid ridge meningiomas and 32% for posterior fossa meningiomas ( Table 2) .
Mortality
There were 16 postoperative deaths. The absolute 5-, 10-, and 15-year survival probability was 83%, 77%, and 69%, respectively (Fig. 2) . If death from intercurrent disease is excluded, the determinate 15-year survival probability was 89%.
Factors in Recurrence or Progression
Extent of Surgery. Following a total resection, the actuarial recurrence-free survival rate at 5, 10, and 15 years was 93%, 80%, and 68%, respectively, for all sites. In contrast, after a subtotal excision, the actuarial pro-R. O. Mirimanoff, et al. gression-free survival rate during the same period was only 63%, 45%, and 9%, respectively (Fig. 3 left) . This difference was highly statistically significant (p < 0.0001). The probability of not having a second operation following a total resection after 5, 10, and 15 years was 94%, 85%, and 80%, whereas after a subtotal excision the probability of not having a second operation was 75%, 56%, and 16%, respectively (Fig. 3 right) .
Again, this difference was highly statistically significant (p < 0.0001). Thus, not all patients with tumor recurrence or progression underwent another operation. The exact reasons for this were difficult to assess retrospectively. Common causes appeared to be medical inoper-
.,. ability, refusal of a second operation by the patient, and insufficient increase in the patient's symptoms to warrant surgery, especially in older patients. Tumor Location. The probability of survival free of recurrence or progression varied according to tumor site, as shown in Fig. 4 . For example, sites with a low recurrence/progression rate at 5 and 10 years, respectively, were the spine (0% and 13%), convexity (3% and 25%), and parasagittal area (18% and 24%). An intermediate risk of recurrence or progression was found for parasellar meningiomas (19% and 35%). Sphenoid ridge meningiomas had the highest risk of recurrence or progression at 5 and 10 years (34% and 54%). Generally, tumor sites associated with the highest total resection rate had the lowest probability of recurrence or progression, and locations in which only a few tumors could be removed in toto had a higher probability of recurrence or progression. However, olfactory groove meningiomas, with a total resection rate of 77%, had a rather high probability of recurrence or progression (30% at 5 and 41% at 10 years) and were an exception to this rule. Admittedly, the number of patients in this group who were at risk after 5 years was small.
Sex and Age. The recurrence-free or progressionfree survival rates at 5 and 10 years were almost identical for females (83% and 68%) and for males (84% and 66%). There was no significant difference in these rates at 5 and 10 years between patients less than 50 years old (83% and 61%) and those more than 50 years old (84% and 75%) (p = 0.48).
Duration of Symptoms. The length of time from
the first symptom to operation was less than 6 months for 59 patients, 6 months to 1 year for 54 patients, 1 year to 2 years for 60 patients, and more than 2 years for 52 patients. There was no significant difference in recurrence-free or progression-free rates between these four groups at 10 years (76%, 63%, 65%, and 71%, respectively).
Second Resection
Of the 33 patients who underwent a second operation, two died postoperatively and three were lost to follow-up review. Of the 28 remaining patients, the probability of survival at 5 and 10 years without a third resection after the second resection was 58% and 44%, respectively (Fig. 5) . Nineteen of the 28 patients did not undergo a third operation: one died from progressive tumor after less than 1 year; one had radiological signs of progression at 1 year; three had known residual meningioma that was stable at 4, 6, and 16 years; and four died of intercurrent disease, all within 1 year of the second operation. Thus, only 10 of the 19 patients were alive without evidence of meningioma with a mean follow-up period of 4 years.
Discussion
We undertook this study to evaluate the results of surgery as the sole modality of treatment in operable patients with meningioma at the MGH and to define the potential role of radiotherapy in the management of these tumors. Although there are a number of publications regarding radiotherapy in the treatment of meningioma, 3'7-9,t4,29-31 the role and value of this modality remains a controversial subject. One of the reasons for this is the fact that, with modem surgery, the operative and long-term mortality rates are low and have steadily decreased over the past decades. ~6'8' 2~ In our series, the determinate 15-year survival probability was 89%. However, mortality is not the only issue, since the functional capabilities of the patients who survive are very often impaired. 6 Many patients are afflicted with blindness, motor deficits, and epilepsy. Because functional status is quite difficult to evaluate objectively in a retrospective study, we chose to assess tumor recurrence or progression, and used only objective criteria (that is, radiological signs and the need for a second operation). Thus, we know that our results indicate a lower rate of recurrence or progression than might actually occur.
Despite the very large number of publications on meningiomas, only a minority evaluate the problem of recurrence. 1,12,19,26,3~ Furthermore, in most of these reports the method of statistical analysis is quite simplistic. For example, Jellinger and Slowik,12 in reporting their cases, stated that "the incidence of recurrence in the total series was 10.5%." Defining a recurrence rate simply as a proportion of all patients treated, irrespective of the follow-up period, will often grossly underestimate the ultimate recurrence rate. To illustrate this point further, we will consider our own data regarding recurrences after total excision. Altogether, 16 of 145 patients in our series had tumor recurrence for a recurrence rate of 11%. However, this percentage is not a useful figure because of varying follow-up times. Using life-table analysis, we computed a risk of recurrence after a total resection of 7% at 5 years, 20% at 10 years, and 32% at 15 years. This is quite different from 1 1%. This method of analysis is particularly important in a condition such as meningioma because late recurrences are common. To our knowledge, this method of analysis has been used in only one recent meningioma study.
Thus, our study demonstrates that the recurrence
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rate after a complete resection is significant and that the probability of undergoing a second operation in this group is 6%, 15%, and 20% at 5, 10, and 15 years, respectively. These figures may appear surprising since we carefully excluded multiple meningiomas and malignant meningiomas. It is likely that in some instances the meningioma was thought to have been totally removed when in fact some residual tumor was left in place, particularly since many operations in the study period (1962 to 1980) predated the use of the operative microscope and CT scanning. In contrast to totally excised meningiomas, subtotally removed tumors had a high probability of progression at 5, 10, and 15 years (37%, 55 %, and 9 t %, respectively) and a high probability of requiring a second operation (25%, 44%, and 84%, respectively).
Lesions at certain sites were associated with a higher recurrence or progression rate, and this was generally related to the extent of surgery. Extreme examples are meningiomas of the sphenoid ridge (with a total resection rate of 28% and a recurrence/progression probability at 5 and 10 years of 34% and 54%), and of the convexity (with a total resection rate of 96% and a recurrence/progression probability at 5 and 10 years of 3% and 25%). A neurosurgeon may have difficulty in totally removing a tumor at some sites, and may also be unable to ascertain whether the meningioma has been totally extirpated.
In our series, following a second resection the probability of having a third resection was 42% at 5 and 56% at 10 years. Among patients who were not operated on for a third time, only 10 were alive and free of signs of meningioma, with a mean follow-up period of 4 years.
A major objective of this study was to better define those subgroups of patients with meningioma who have a higher chance of developing tumor progression or recurrence, so that early postoperative intervention with other treatment modalities might be considered. In this regard, two forms of adjunctive therapy should be considered: medical therapy and radiotherapy.
Medical treatment of meningiomas has only been considered a possibility. The striking female preponderance in this series and in most other large studies, as well as the association of meningiomas with breast cancer 25 and the documented enlargement of meningiomas with pregnancy 2 have prompted a number of investigators to postulate a mechanism of hormonal modulation of these tumors. Early studies 5'22'24 suggested that a small number of meningiomas contained cytoplasmic receptors for estrogen, raising the possibility of hormonal therapy using estrogen-blocking agents. Later studies, 28 some in preparation, show that an elevated level of cytoplasmic progesterone receptors may be a more significant feature of these tumors, and intervention with progesterone-receptor mechanisms presents an alternate approach. However, to date there have been no published reports on in vitro or in vivo tumor growth through hormonal manipulations. There-fore, it remains unclear whether tumor inhibition is possible using hormonal means, and whether hormonal augmentation or blocking has a potential role in the management of meningiomas. More biological data will be needed before clinical studies can be conducted.
In contrast, radiotherapy, either alone or in conjunction with surgery, has been used by several centers in the treatment of meningiomas. 3'7-9'14'29-31 King, et al., 14 have stated that meningiomas must generally be considered radioresistant. However, the details regarding the doses and the techniques used in their study are insufficiently described. It should be emphasized here that a number of malignant as well as benign tumors that have been traditionally considered radioresistant have been recently found to be curable by radiotherapy alone or in combination with other treatment modalities. Soft-tissue sarcomas 27 and desmoids 13 belong in this category, and perhaps meningiomas represent another example. The most convincing evidence for the use of radiotherapy in conjunction with surgery for meningiomas comes from the work of Wara, et al. 3~ Of 58 of their patients who underwent a subtotal excision and no radiotherapy, 27 had recurrence within 5 years, nine between 5 and 10 years, and seven between l0 and 20 years after excision. In contrast, of 34 patients who received radiotherapy after a subtotal resection, only six had a recurrence within 5 years, one between 5 and 10 years, and three between 10 and 20 years after resection. Patients were generally treated with megavoltage radiation and received doses of 45 to 55 Gy at 1.8 Gy per fraction. Carella, et al.,3 have also provided convincing evidence for the role of radiotherapy after incomplete surgery, for recurrences, or even on occasion as primary treatment. They recommended doses of 50 to 55 Gy directed at a small field. Their data showed that not only can radiotherapy play an important role after incomplete resection, but it can provide substantial palliation in patients with inoperable tumors. In this regard, Van Effenterre, et al., 29 treated eight patients with inoperable meningiomas of the cavernous sinus with high-energy radiotherapy (to about 55 Gy). Oculomotor palsies regressed in all eight patients and disappeared completely in three of them. Unfortunately, long-term follow-up data are lacking in this study.
Conclusions
Surgery is the accepted form of treatment for meningiomas but it may prove insufficient as the only method of therapy in certain situations. With the advent of CT scanning and microsurgery, and with improved preand postoperative care, morbidity and mortality rates have been reduced, but it will take several years before the results of follow-up studies are available in other large series of meningioma patients. Our study demonstrated that, in certain sites, after either a subtotal excision or a second resection, the recurrence or progression rates were high. Despite two recent convincing reports showing that radiotherapy can prevent recurrence after subtotal excision, or that it can even control unexcised or recurrent meningiomas, the role of radiotherapy for meningiomas is still a controversial subject. Many neurosurgeons and radiotherapists will hesitate to consider radiotherapy for meningiomas because of the indolent nature of the disease and the potential for radiation-induced damage. However, with the development of the newer methods of radiation therapy, this treatment modality must be considered in the overall treatment plan.
